Status:
COMPLETED
Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known ...
Eligibility Criteria
Inclusion
- Active rheumatoid arthritis
- Incomplete response to methotrexate
Exclusion
- Must not be on biologic therapies
- No recent infections
Key Trial Info
Start Date :
April 7 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 4 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00628095
Start Date
April 7 2008
End Date
February 4 2009
Last Update
April 4 2022
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Arthritis & Rheumatology Associates, P.C.
Mesa, Arizona, United States, 85202
2
Omega Research Consultants LLC
DeBary, Florida, United States, 32713
3
Florida Arthritis Center
Lake Mary, Florida, United States, 32746
4
Tampa Medical Group, PA
Tampa, Florida, United States, 33614